Unknown

Dataset Information

0

Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study.

ABSTRACT: Drs. Ramalingam and Carlisle discuss the incidence and pathophysiology of BRAF V600E-mutant metastatic non-small cell lung cancer and current treatment options. The podcast provides an overview of the data from the recent Pfizer-sponsored phase 2 PHAROS (NCT03915951) study, which were the basis for the recent US Food and Drug Administration approval of encorafenib plus binimetinib for BRAF V600E-mutant metastatic non-small cell lung cancer.

SUBMITTER: Ramalingam SS 

PROVIDER: S-EPMC11537293 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study.

Ramalingam Suresh S SS   Carlisle Jennifer W JW  

Future oncology (London, England) 20240903 33

Drs. Ramalingam and Carlisle discuss the incidence and pathophysiology of BRAF V600E-mutant metastatic non-small cell lung cancer and current treatment options. The podcast provides an overview of the data from the recent Pfizer-sponsored phase 2 PHAROS (NCT03915951) study, which were the basis for the recent US Food and Drug Administration approval of encorafenib plus binimetinib for BRAF V600E-mutant metastatic non-small cell lung cancer. ...[more]

Similar Datasets

Unknown Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.
| S-EPMC12680272 | biostudies-literature
Unknown Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
| S-EPMC7260582 | biostudies-literature
Unknown Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma.
| S-EPMC11096001 | biostudies-literature
Unknown POLARIS: encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis.
| S-EPMC12266674 | biostudies-literature
Unknown Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC.
| S-EPMC9271477 | biostudies-literature
Unknown Updated result from the phase 2 PHAROS study: has the sustained efficacy and tolerability of encorafenib plus binimetinib been demonstrated in patients with <i>BRAF</i> V600E-mutant metastatic non-small-cell lung cancer?
| S-EPMC12780439 | biostudies-literature
Unknown Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.
| S-EPMC9271503 | biostudies-literature
Unknown Encorafenib plus cetuximab for the treatment of <i>BRAF-V600E</i>-mutated metastatic colorectal cancer.
| S-EPMC9260564 | biostudies-literature
Unknown BRAF<sup>V600E</sup>-mutant metastatic NSCLC: disease overview and treatment landscape.
| S-EPMC11021522 | biostudies-literature
Unknown Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.
| S-EPMC7370699 | biostudies-literature